• Do drug-coated balloons have a “class effect,” or does each DCB need to be studied on its own?
• What do the 3-year IN.PACT SFA safety and durability results mean for patient care?
• Is it time for a paradigm shift to IN.PACT Admiral as a first-line treatment for symptomatic femoropopliteal disease?
For answers to these and other questions, watch this only-at-VIVA video, featuring LBCT presenter Prakash Krishnan, MD, complete with comments from moderators including Krishna Rocha-Singh, MD, and panelist Tony Das, MD.
Join VIVA 17 September 11-15, 2017 at Wynn Las Vegas!